HOLON, Israel, Sept. 27,
2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ:
CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company
and a pioneer in computational target discovery,
today announced, it will present new clinical and
pre-clinical data supporting its vision to extend the reach of
cancer immunotherapies to new patient populations, in an oral
presentation and four poster presentations at the
38th Annual Meeting of the Society for Immunotherapy of
Cancer (SITC), taking place between 3-5
November 2023, San Diego,
CA.
Oral presentation details:
Abstract Title: Harnessing natural IL-18 activity
through IL-18BP blockade reshapes the tumor microenvironment for
potent anti-tumor immune response
Abstract number: 550
Presenter: Eran
Ophir
Session: Cytokines in Cancer
Date: Friday, November 3,
2023
Time: 3:30 PM - 5:10 PM
PDT
Poster presentation details:
Abstract Title: Immune modulation and baseline biomarker
correlation with clinical benefit following treatment with COM701 +
nivolumab +/- BMS-986207 in patients with platinum resistant
ovarian cancer
Abstract Number: 29
First Author: Gady
Cojocaru
Date: Friday, November 3,
2023
Abstract Title: Durable responses with triple blockade of
the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients
with platinum resistant ovarian cancer
Abstract Number: 669
First Author: Stephanie
Gaillard
Date: Friday, November 3,
2023
Abstract Title: Harnessing natural IL-18 activity through
IL-18BP blockade reshapes the tumor microenvironment for potent
anti-tumor immune response
Abstract number: 550
First Author: Assaf
Menachem
Date: Saturday, November 4,
2023
Abstract Title: The combination of COM701 + nivolumab
demonstrates preliminary antitumor activity in patients with
metastatic breast cancer
Abstract Number: 640
First Author: Ecaterina
Dumbrava
Date: Saturday, November 4,
2023
Compugen's abstracts will be available on the publications
section of Compugen's website, www.cgen.com
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bi-specific derived from COM902, in Phase 2
development by AstraZeneca through a license agreement for the
development of bi-specific and multi-specific antibodies. In
addition, the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of programs
aiming to address various mechanisms of immune resistance. The most
advanced program, COM503 is in IND enabling studies. COM503 is a
potential first-in-class, high affinity antibody which blocks the
interaction between IL-18 binding protein and IL-18, thereby
freeing natural IL-18 to inhibit cancer growth in the tumor
microenvironment. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-present-new-clinical-and-pre-clinical-data-in-multiple-presentations-at-sitc-2023-301940169.html
SOURCE Compugen Ltd.